I recommend selling shares of Immunogen (SYM: IMGN) here at $29.89.

For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.

Shares of one of Immunogen (SYM: IMGN) are set to open up 94% after AbbVie agreed to buy the company for $31.26. 

Exciting news on core holding Immunogen (SYM: IMGN) this week.

The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July

Let's start by closing out one of our older positions for a small profit. 

ImmunoGen Inc. (SYM:IMGN) added 17% pre-market this morning to $16.50, a 211% gain from our recommended price of $5.30.

Shares of one of ImmunoGen (SYM: IMGN) are up 100% today after the company posted great Phase 3 trial results for its ovarian cancer drug, Elahere.

An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.

For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.